Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2490
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer ; volume:11 ; number:1 ; day:14 ; month:5 ; year:2011 ; pages:1-6 ; date:12.2011
BMC urology ; 11, Heft 1 (14.5.2011), 1-6, 12.2011
- Urheber
-
Fujimoto, Naohiro
- Beteiligte Personen und Organisationen
-
Kubo, Tatsuhiko
Shinsaka, Hideo
Matsumoto, Masahiro
Shimajiri, Shohei
Matsumoto, Tetsuro
SpringerLink (Online service)
- DOI
-
10.1186/1471-2490-11-7
- URN
-
urn:nbn:de:1111-2016071624398
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Fujimoto, Naohiro
- Kubo, Tatsuhiko
- Shinsaka, Hideo
- Matsumoto, Masahiro
- Shimajiri, Shohei
- Matsumoto, Tetsuro
- SpringerLink (Online service)
Ähnliche Objekte (12)
PTP1B regulates lymphocytes responses androgen deprivation
Androgen deprivation modulates the inflammatory response induced by irradiation
Androgen receptor expression in the clinically localized prostate cancer
Androgen regulation of the androgen receptor coregulators
Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Androgen deprivation in prostate cancer: benefits of home-based resistance training
Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer
Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation
Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
PTP1B regulates lymphocytes responses androgen deprivation
Androgen deprivation modulates the inflammatory response induced by irradiation
Androgen receptor expression in the clinically localized prostate cancer
Androgen regulation of the androgen receptor coregulators
Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Androgen deprivation in prostate cancer: benefits of home-based resistance training
Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer
Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation
Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
PTP1B regulates lymphocytes responses androgen deprivation
Androgen deprivation modulates the inflammatory response induced by irradiation
Androgen receptor expression in the clinically localized prostate cancer
Androgen regulation of the androgen receptor coregulators
Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Androgen deprivation in prostate cancer: benefits of home-based resistance training
Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer
Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation
Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer